|
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes |
Jan 2021 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management |
Nov 2020 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Clinical decision-making and treatment of myelodysplastic syndromes |
Dec 2023 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Complement inhibition in medicine: Hematology and beyond; complement inhibition in hematology: PNH and beyond |
May 2023 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management" |
Mar 2021 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Paroxysmal nocturnal hemoglobinuria: Where we stand |
May 2023 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Paroxysmal nocturnal hemoglobinuria: Where are we going |
May 2023 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes |
Nov 2019 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria |
Apr 2021 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
How I Diagnose Low-Grade Myelodysplastic Syndromes |
May 2020 |
American Journal of clinical Pathology |
Myelodysplastic Syndromes (MDS) |
